Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit
Malak Sabbah(Institut Jules Bordet), Fabrice Journé(Université Libre de Bruxelles)
Cited by 8
Related Papers
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells
|British Journal of Cancer|2004|22
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells
|Breast Cancer Research|2008|15
ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
|Cancer Cell International|2024|9
Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy
|International Journal of Molecular Sciences|2025|5